TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858036
Drug: Ricrolin+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
Study: NCT02158182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.
Study: NCT02006160
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bid
Study: NCT01219322
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous normal saline volume equivalent to sodium bicarbonate
Study: NCT01413581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
Study: NCT03447262
Drug: VX-659/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration qd in the morning.
Study: NCT02548403
Drug: PEG-Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study: NCT02841098
Drug: Optimal medical therapy alone
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone
Study: NCT02680132
Drug: Nexium 40 mg DR Capsules of AstraZeneca LP, USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, cross over
Study: NCT00317720
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
Study: NCT04349592
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study: NCT01758627
Drug: Peritoneal dialysis (PD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
Study: NCT00318214
Drug: MRE0094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel, 500 mcg/g once each day
Study: NCT00318214
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel administered once per day
Study: NCT01395875
Drug: Anticholinergics (AC)
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
Study: NCT01788033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
Study: NCT00281645
Drug: Standard of Care (pharmacological analgesic treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03163589
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT01414972
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cap placebo/day for 3 month
Study: NCT03636763
Drug: data report
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: the information gliptin exposure will be reported
Study: NCT00524264
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo
Study: NCT01342484
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug (low vs high) vs placebo
Study: NCT00126191
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
Study: NCT00126191
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
Study: NCT00126191
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
Study: NCT01292720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in matching volumes
Study: NCT00126191
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
Study: NCT00617877
Drug: Comparator: Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Study: NCT03143803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar looking inactive powder
Study: NCT02431416
Drug: Gonadotropin releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
Study: NCT02603770
Drug: XueZhiKang
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603770
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02164929
Drug: Acetaminophen 1g IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02164929
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1:200,000 epinephrine
Study: NCT00385593
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00304083
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00532090
Drug: RG4733
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily at ascending doses to successive cohorts of patients
Study: NCT00532090
Drug: RG4733
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
Study: NCT00532090
Drug: RG4733
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
Study: NCT04351555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02456935
Drug: CJ-12420 100 mg QD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
Study: NCT00227136
Drug: 5-Hydroxy-Tryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03543189
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care.
Study: NCT00781586
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 100 mg 1 tablet at 1st visit
Study: NCT00781586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet at 1st visit
Study: NCT01165905
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
Study: NCT01970215
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01970215
Drug: Placebo Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00999791
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02499328
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150
Study: NCT03938246
Drug: TVB-2640 50 mg (US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT03938246
Drug: Placebo (US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT00415363
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT03061734
Drug: Naltrexone and Acetaminophen
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone plus acetaminophen
Study: NCT03061734
Drug: Naltrexone and Acetaminophen-High Dose
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexon (high dose) plus acetaminophen
Study: NCT03938246
Drug: TVB-2640 75 mg (US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT03061734
Drug: Acetaminophen Alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen Alone plus Placebo
Study: NCT03061734
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Placebo capsules
Study: NCT02134834
Drug: OP0595
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Study: NCT02134834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Study: NCT00631020
Drug: Optional NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NicoDerm CQ nicotine transdermal patch
Study: NCT03295877
Drug: RO7171009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive RO7171009 via ITV injection.
Study: NCT00068744
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01179464
Drug: Aminobiphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard intravenous biphosphonate treatment
Study: NCT01179464
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg once daily
Study: NCT02243254
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous ibuprofen
Study: NCT02053116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, twice daily, 2 weeks
Study: NCT02197247
Drug: AZD9291 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
Study: NCT01821612
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01821612
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO
Study: NCT00544882
Drug: Mircette®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Study: NCT00544882
Drug: Kariva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Study: NCT02359617
Drug: insulin delivery
Normalized name: Insulin Delivery Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
Study: NCT03619408
Drug: Antacids
Normalized name: ANTACIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
Study: NCT01231490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01231490
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule
Study: NCT04374136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT03318471
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
Study: NCT00479258
Drug: Inhaled insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study: NCT02985593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03480776
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg PO daily or 325 mg PO daily
Study: NCT01746017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT01746017
Drug: LY2922470
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT03422653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication delivered three times/week
Study: NCT01825447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
Study: NCT03199547
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Study: NCT03199547
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Study: NCT04132622
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
Study: NCT04132622
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: including steroids, vitamin C, hemodialysis and blood perfusion.
Study: NCT04037748
Drug: Puran T4®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
Study: NCT04037748
Drug: Eutirox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
Study: NCT00871182
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, inhaled
Study: NCT04998838
Drug: Regular Myanmar treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated according to normal Myanmar processes for HBV positive patients
Study: NCT01390766
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00771485
Drug: Marketed Bowel Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed bowel cleanser
Study: NCT01215266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 3-21 2x2 800 mg(milligram) daily
Study: NCT03152981
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Study: NCT01856205
Drug: Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate.
Study: NCT01375660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
Study: NCT03653260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injector, 20 Bar pressure, empty injector
Study: NCT00162474
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03473249
Drug: Contrast-Enhanced Ultrasound using Lumason
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
Study: NCT03660020
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
Study: NCT00496964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
Study: NCT00303784
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Study: NCT01091974
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 47 days
Study: NCT01820364
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
Study: NCT03451084
Drug: ASLAN003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
Study: NCT00966342
Drug: Fluviral 2009/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given IM .05 mL
Study: NCT00398580
Drug: Nanomilled testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00909610
Drug: Urso Forte™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urso Forte™ Tablets, 500 mg
Study: NCT00454259
Drug: Fentanyl/Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra low dose intravenous injection
Study: NCT02349594
Drug: Omegaven 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
Study: NCT00077363
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03292809
Drug: CyclASol topical ocular, eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A solution in vehicle
Study: NCT03292809
Drug: Vehicle topical ocular, eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03013634
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal volume normal saline substitute for dexmedetomidine
Study: NCT00857935
Drug: NatrOVA Creme Rinse - 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
Study: NCT02326610
Drug: Human growth hormone,ZOMACTON® (somatropin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
Study: NCT01482377
Drug: RO5479599
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
Study: NCT02919631
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil
Study: NCT01702714
Drug: RO5083945
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending doses
Study: NCT02777268
Drug: Infacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-particulate granules
Study: NCT02777268
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT01355757
Drug: Single Injection of Local Anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 20 ml ropivacaine 0.5%